Gossamer Bio, Inc. (GOSS) |
|
1.175 0.105 (9.81%)
|
03-24 11:47 |
|
Open: |
1.07 |
Pre. Close: |
1.07 |
|
High:
|
1.19 |
Low:
|
1.06 |
|
Volume:
|
1,478,153 |
Market Cap:
|
112(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 10:44:05 AM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 2.05  One year: 2.62 |
| Support: |
Support1: 0.95 Support2: 0.79 |
| Resistance: |
Resistance1: 1.75 Resistance2: 2.25 |
| Pivot: |
1.28 |
| Moving Average: |
MA(5): 1.14 MA(20): 1.4
MA(100): 3.9 MA(250): 7.74 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 16.5 %D(3): 18.6 |
| RSI: |
RSI(14): 35.1 |
| 52-week: |
High: 15.19 Low: 0.95 |
| Average Vol(K): |
3-Month: 4,143 (K) 10-Days: 7,480 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ GOSS ] has closed above bottom band by 34.2%. Bollinger Bands are 69.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 60 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.28 - 1.29 |
1.29 - 1.3 |
|
Low:
|
1.04 - 1.05 |
1.05 - 1.06 |
|
Close:
|
1.06 - 1.07 |
1.07 - 1.08 |
|
Company Description |
|
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California. |
Headline News |
Fri, 24 Mar 2023
Q1 2023 EPS Estimates for Gossamer Bio, Inc. Increased by Analyst ... - MarketBeat
Thu, 23 Mar 2023
Gossamer Bio, Inc. to Post Q1 2023 Earnings of ($0.46) Per Share ... - MarketBeat
Thu, 23 Mar 2023
Co-Founder Faheem Hasnain Just Bought 23% More Shares In Gossamer Bio, Inc. (NASDAQ:GOSS) - Simply Wall St
Wed, 22 Mar 2023
What is the Market's View on Gossamer Bio Inc (GOSS) Stock's Price and Volume Trends Wednesday? - InvestorsObserver
Mon, 20 Mar 2023
Why Bed Bath & Beyond Shares Are Trading Lower By Around 24 ... - Investing.com UK
Mon, 20 Mar 2023
Healthcare Stocks Moving Up and Down Monday: LFCR, ACER, INM, GOSS, AZYO, CODX, OMGA, SOPH - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
94 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
4.8 (%) |
|
% Held by Institutions
|
119.3 (%) |
|
Shares Short
|
26,620 (K) |
|
Shares Short P.Month
|
25,350 (K) |
Stock Financials |
|
EPS
|
-2 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.6 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-0.58 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
1.92 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
